South America Pancreatic Cancer Therapeutics and Diagnostics Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

South America Pancreatic Cancer Therapeutics and Diagnostics Market Trends and Insights

Increasing Pancreatic Cancer Burden Accelerates Treatment Demand

The rising pancreatic cancer burden supported demand in the South American pancreatic cancer therapeutics and diagnostics market. A January 2025 analysis reported that Brazil’s age-standardized incidence increased by 0.7% annually from 1990 to 2019 for both sexes, while Peru recorded the region’s sharpest increase, at 3.0% to 3.9% annually. Brazil’s annual case volume rose from 4,431 in 1990 to 14,430 in 2019, while Argentina recorded incidence rates of 12.7 per 100,000 men and 10.5 per 100,000 women, with rising mortality trends.^{[1]International Agency for Research on Cancer, “South America Fact Sheet,” Global Cancer Observatory, gco.iarc.who.int} INCA projected 10,980 new pancreatic cancer cases annually in Brazil during the 2023–2025 estimation period, highlighting the need to expand treatment capacity beyond metropolitan hospitals.^{[2]Instituto Nacional de Câncer, “Estimativa 2023-2025 Incidência de Câncer no Brasil,” Revista Brasileira de Cancerologia, rbc.inca.gov.br}

Expansion of Advanced Oncology Diagnostics Creates New Revenue Pools

Advanced diagnostics expanded beyond a limited number of metropolitan laboratories in the South American pancreatic cancer therapeutics and diagnostics market. Greater adoption of molecular testing linked diagnostic demand with targeted therapy approvals, as each treatment target required reliable patient identification before prescribing decisions. Companion diagnostics became increasingly integral to treatment access rather than a standalone laboratory service. Centralized laboratory models improved sample logistics and reporting capabilities for hospitals outside major cancer centers, supporting diagnostic revenue growth through biomarker selection and genomic profiling.

Rising Use of Combination Chemotherapy Regimens Sustains Therapeutic Market

Combination chemotherapy remained a key source of treatment activity in the South America pancreatic cancer therapeutics and diagnostics market. FOLFIRINOX was used for fit patients with metastatic pancreatic ductal adenocarcinoma, while gemcitabine plus nab-paclitaxel remained an established option. A Latin American single-center study found that gemcitabine plus nab-paclitaxel after FOLFIRINOX progression delivered outcomes comparable with Western and Asian benchmarks. NALIRIFOX demonstrated median overall survival of 11.1 months versus 9.2 months for gemcitabine plus nab-paclitaxel, and median progression-free survival of 7.4 months versus 5.6 months, increasing infusion, imaging, laboratory monitoring, and supportive care requirements.

Growth of Precision Oncology and Biomarker Testing Unlocks Targeted Therapy Access

Precision oncology became increasingly established in the South America pancreatic cancer therapeutics and diagnostics market. In February 2025, MGI Tech partnered with Oncoclínicas&Co to install the DNBSEQ-G400 sequencer at OC Medicina de Precisão in São Paulo. The center supported 1,000 genomic samples per month, including germline cancer-syndrome and somatic panels, while Oncoclínicas&Co operated 144 units across 40 Brazilian cities. Brazil’s Genomas Brasil program integrated large-scale genomics into the Unified Health System infrastructure, and KRAS profiling remained relevant as KRAS mutations occurred in more than 90% of pancreatic ductal adenocarcinoma cases.

High Cost of Multimodal Treatment and Molecular Testing Limits Addressable Volume

High treatment and testing costs restricted the addressable patient population in the South American pancreatic cancer therapeutics and diagnostics market. An ISPOR Europe 2025 analysis reported annual oncology treatment costs of USD 50,054 in Brazil and USD 1,992 in Argentina, compared with USD 134,933 in the United States. Public procurement limits and purchasing-power constraints reduced prices but did not ensure access to advanced therapies or molecular tests. Guardant360 was available through reference laboratories, including Diagnósticos do Brasil, but limited coverage mandates kept uptake concentrated among private-pay and supplemental-insurance patients.

Late Diagnosis and Limited Resectability at Presentation Compresses Therapeutic Opportunity

Late diagnosis limited access to curative-intent treatment in the South American pancreatic cancer therapeutics and diagnostics market. INCA-related information indicated that 80% of Brazilian patients were diagnosed with advanced, non-resectable disease, directing demand toward palliative and later-line regimens. The BLENTI study at Hospital do Coração and the mirPANC 2 trial at Beneficência Portuguesa de São Paulo began in January 2025, reflecting demand for earlier, less invasive detection approaches. The mirPANC 2 trial evaluated a serum-based microRNA panel in patients starting FOLFIRINOX, while broader liquid-biopsy adoption required national-payer reimbursement.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Product: Diagnostic Modality Growth Reshaping a Therapeutics-Led Market

Diagnostic modalities are the fastest-growing product category in the South America pancreatic cancer therapeutics and diagnostics market, with a CAGR of 7.55% during 2026-2031. Therapeutics remains the larger revenue-generating category due to the widespread use of systemic treatment in advanced disease management. CT, MRI, and PET remain the highest-volume tools for staging and treatment monitoring, while high-volume centers in São Paulo, Buenos Aires, and Bogotá increasingly use endoscopic ultrasound. Biomarker testing and molecular diagnostics are expanding as treatment selection relies more heavily on genomic information; the February 2025 DNBSEQ-G400 deployment supported 1,000 somatic and germline samples per month.

The diagnostics segment benefits from the wider adoption of centralized testing services and trial-led liquid biopsy development. The mirPANC 2 and BLENTI studies in Brazil supported liquid biopsy evidence generation, while the Panuri study began in June 2026 to assess a urine proteolytic-enzyme test for pancreatic ductal adenocarcinoma detection. Therapeutic demand remains anchored in FOLFIRINOX and gemcitabine plus nab-paclitaxel, while olaparib is relevant for the 4%-7% of patients with germline BRCA mutations and pembrolizumab for the rare MSI-H subset. Immunotherapy remains limited by the immunosuppressive pancreatic tumor microenvironment, while radiotherapy is constrained by limited stereotactic body radiotherapy capacity outside major academic centers; ImmunityBio updated its Phase 1 neoadjuvant chemoimmunotherapy protocol in April 2026.

By End User: Diagnostic Laboratories Gaining Share Fastest as Molecular Testing Scales

Diagnostic laboratories are the fastest-growing end-user group in the South America pancreatic cancer therapeutics and diagnostics market, with a forecast CAGR of 8.56% during 2026-2031. Hospitals and academic medical centers retain the largest revenue position due to their provision of chemotherapy, advanced imaging, endoscopic procedures, and inpatient care. Laboratories are expanding as hospitals outsource comprehensive genomic testing when they lack in-house sequencing and bioinformatics capabilities. Guardant360 availability through reference laboratory networks supports centralized sample management, molecular result delivery, and companion diagnostic workflows.

Hospitals and academic medical centers remain critical for infusion-based treatment, complex imaging, and endoscopic procedures. Oncoclínicas&Co delivered 635,000 treatments annually across 144 units in 40 Brazilian cities, making it an important access point for pharmaceutical and diagnostic companies. Oncology specialty clinics are receiving a larger share of day-treatment chemotherapy as FOLFIRINOX moves from inpatient settings. Research institutes contribute through trial-linked imaging, pathology, and molecular workflows, while the industry favors hospitals for treatment delivery and laboratories for scalable molecular diagnostics.

Geography Analysis

Brazil held 46.96% of the South America pancreatic cancer therapeutics and diagnostics market share in 2025, supported by its established oncology infrastructure and position as the region’s primary regulatory and commercial gateway. The Genomas Brasil program integrated precision genomics into the Unified Health System and could expand testing beyond the private-pay base in São Paulo and Rio de Janeiro. ANVISA registered Onivyde in April 2025, and Servier made it commercially available at Brazilian oncology centers in February 2026.

The São Paulo corridor included Oncoclínicas&Co, Hospital do Coração, Beneficência Portuguesa, and AC Camargo Cancer Center, supporting clinical trial enrollment and complex diagnostic procedures. This concentration attracted diagnostic platform deployments and pharmaceutical sponsor activity. SUS genomic capacity could increase molecular testing volumes in secondary cities during the forecast period, and Brazil will remain the main source of regional treatment and diagnostic demand.

Colombia, Chile, Peru, and the rest of South America accounted for the remaining regional revenue share. Colombia’s age-standardized incidence declined by 0.5% annually from 1990 to 2019, although absolute cases increased with population growth and private diagnostic capacity expanded in Bogotá and Medellín. Chile showed no significant incidence change and recorded steady growth, supported by its public-private healthcare structure. Peru recorded the region’s sharpest annual incidence increase, ranging from 3.0% to 3.9% for both sexes, while cancer infrastructure at INEN and EsSalud remained a limiting factor. Differences in diagnostic access and treatment capacity between capital-city hubs and outlying areas shaped the South America pancreatic cancer therapeutics and diagnostics market.